To the editor:
staining should be interpreted with great care. It cannot be In a recent paper in Cardiovascular Research, Verheijck ruled out that immunostaining with the anti-Cx45 antibody et al. [1] examine the important topic of the electroin these areas is due to cross-reaction with Cx43''. In fact, physiological properties of the sinoatrial (SA) node in the Cx45 antibody used by Coppen and colleagues to relation to the distribution of different connexin types. It is investigate Cx45 distribution manifestly does not react certainly pleasing to see that these authors' results and with Cx43; it was the anti-Cx45 antibody supplied by conclusions on connexin distribution in the mouse SA
Chemicon that showed such cross-reactivity as does the node in many respects parallel our earlier published anti-Cx45 antibody used by Verheijck et al. . This antibody was raised against a peptide appraising and advancing investigation of the spatial and corresponding to residues 354-367 of human Cx45, and temporal expression patterns of Cx45 in cardiovascular and when first applied 5 years ago, showed quite different other tissues [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . From this perspective, we feel it labelling patterns from those previously reported for Cx45 imperative that the record be set straight.
in the heart, in particular revealing preferential distribution The authors state that ''Coppen et al. [3] showed that the of Cx45 label in the ventricular conduction system but Cx45 antibody they used cross-reacts with the same fournegligible or low levels of Cx45 label in the working amino acid sequence of Cx43. Therefore, dual labelling ventricle [3,9]. By contrast, earlier studies using a Cx45 which shows co-localisation of Cx43 and Cx45 immunoantibody raised to a different peptide sequence (corresponding to residues 285-298 of dog Cx45 which are identical in mouse and human Cx45) had been reported to as that used to produce the antibody used in the studies suppliers' unsubstantiated claims. The solution, as we have pre-dating the work of Coppen and colleagues. The peptide emphasised elsewhere [11] , is characterisation of all antigen to which this earlier antibody and its commercial connexin antibodies using a comprehensive range of counterpart was raised has a sequence of four amino acids techniques with valid positive and negative controls (e.g., (PPGY) which is also present in the Cx43 molecule, transfected cells) and including immunogold electron ]] thereby raising the possibility of cross-reactivity of these microscopy. This is quite distinct from controls in which antibodies with Cx43. Coppen et al. [3] demonstrated that the primary antibody is omitted, pre-immune serum is the widespread labelling of working ventricle given by the substituted and competitive peptide inhibition applied-as Chemicon anti-Cx45 antibody is inhibited by concurrent conducted by Verheijck et al.
[1]-which help check incubation with a six-amino acid peptide corresponding to specificity of labelling, but do not confirm specificity of part of the Cx43 molecule in which the four-amino acid the antibody for its target protein. Successful peptide segment (SPPGYK) common to the Chemicon antigen is inhibition shows that the antibody binds to the peptide to ]] included, thereby confirming cross-reactivity of the which it was raised-it does not demonstrate specificity of Chemicon anti-Cx45 antibody with Cx43. Again, it must detection for the connexin under investigation. As highbe emphasised that this non-specific Cx45 antibody has lighted above, another connexin, or even an unrelated never been used by Coppen et al. to investigate the protein, may present an epitope that a sub-population of distribution of Cx45 in the SA node or any other tissues.
antibodies within an antiserum recognises. The act of Chemicon eventually admitted the cross-reactivity problem purchase does not exonerate the user from demanding the of their original Cx45 antibody when several years later same standard of evidence for specificity as would be they introduced new Cx45 antibodies which they had required for an antibody made in their own laboratory. If raised against the same peptide antigen as used by Coppen this evidence is not forthcoming from the supplier, then, if to generate the anti-Cx45 antibody Q14E(GP42) instead of the purchaser wishes to use the reagent, they must themtheir earlier antigen (Chemicon Communications Update, selves undertake the necessary characterisation work. volume 9, number 4).
Verheijck et al.
[1] go on to state that ''the anti-Cx45 antibody in our study is from another source as the one References used by Coppen et al.'' but ''it is raised against the same peptide sequence''. These statements need to be clarified. 
